The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data
Open accessAbstract
BACKGROUND: Linezolid is the first oxazolidinone antimicrobial marketed in the United States. It exhibits monoamine oxidase (MAO) type A and MAO type B inhibitory effects. The concomitant administration of nonselective MAO inhibitors or MAO-A inhibitors with drugs that increase serotonin concentrations is associated with serotonin toxicity. METHODS: We requested from the US Food and Drug Administration all postmarketing adverse event reports regarding linezolid that included serotonin toxicity or any report describing cognitive or behavioral symptoms and autonomic and neuromuscular excitability. We assessed the case summaries obtained from the Adverse Event Reporting System database for serotonin toxicity. A case of serotonin toxicity was defined as having the following: (1) linezolid as the primary suspect drug; (2) concurrent administration of > or =1 secondary suspect drug known to increase serotonin concentrations in the central nervous system; and (3) serotonin toxicity, as defined by the modified Hunter Serotonin Toxicity Criteria or by the reporter. RESULTS: Twenty-nine cases were classified as serotonin toxicity. Patients' ages ranged from 17-83 years, and the ratio of females to males was 1:1. The most common class of drugs received concurrently with linezolid was selective serotonin reuptake inhibitors (26 of 43 patients). Thirteen patients required an intervention to prevent permanent impairment or required hospitalization for the adverse event. CONCLUSION: The use of linezolid with medications that increase concentrations of serotonin in the central nervous system may result in serotonin toxicity. Prescribers must weigh risks and benefits of this combination. Patients and prescribers should be cognizant of signs and symptoms of serotonin toxicity and should initiate appropriate measures if such symptoms develop.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Cited by
The Enterococcus: a Model of Adaptability to Its Environment
García-Solache, M., & Rice, L. B. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-18 · Cited by 754
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707253 · Cited by 694
Self-citationO’Grady, N. P., Barie, P. S., Bartlett, J. G., Bleck, T., Carroll, K., Kalil, A. C., Linden, P., Maki, D. G., Nierman, D., Pasculle, W., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318169eda9 · Cited by 600
Emergency Department Visits for Antibiotic‐Associated Adverse Events
Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008) · Clinical Infectious Diseases · doi:10.1086/591126 · Cited by 535
Algammal, A. M., Hetta, H. F., Elkelish, A., Alkhalifah, D. H. H., Hozzein, W. N., Batiha, G. E.-S., El Nahhas, N., & Mabrok, M. A. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s272733 · Cited by 403
Metadata
- Authors
- Lawrence, K. R., Adra, M., & Gillman, P. K.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06-01
- Volume
- 42
- Issue
- 11
- Pages
- 1578-1583
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2108934165
- Cited by
- 200
- References
- 2
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. https://app.cochat.ai/papers/10.1086/503839
- The paper
- Lawrence, K. R., Adra, M., & Gillman, P. K. (2006). Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. Clinical Infectious Diseases. https://doi.org/10.1086/503839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.